Zylox-Tonbridge develops and manufactures neuro‑ and peripheral‑vascular interventional medical devices with in‑house R&D, proprietary technological platforms, and commercial capabilities. The company emphasizes cost‑efficient manufacturing to produce high‑quality, affordable devices and services. It aims to expand its peripheral product portfolio for peripheral artery disease (PAD) and to offer a more comprehensive vessel preparation solution. Zylox-Tonbridge has entered a strategic partnership with Avinger to introduce OCT‑guided vascular treatment technology into Greater China and to support Avinger's global sales via technology transfer. The collaboration also creates reciprocal distribution opportunities for Zylox‑Tonbridge products in the U.S. and Germany. The company states this deal is a step toward global expansion and accelerating growth in China’s peripheral vascular intervention market.

Total raised

$15M

Funding rounds

1

Latest round

Equity

Latest activity

Mar 2024